Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L G Qiu

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 2, 2016
[Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world]Y L Wan, Y Wang, B C Liu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 22, 2024
[The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia]Y S Huang, W J Xiong, J J Yuan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 7, 2021
[Central nervous system toxicity caused by bortezomib: five case reports and a review of literature]J H Liu, H S Fan, S H Deng, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 26, 2010
Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experienceP Zhang, E-L Jiang, D-L Yang, et al.
Bone Marrow Transplantation|December 20, 2011
An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of ChinaJ Huang, D-H Zou, Z-J Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 25, 2023
[Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma]D D Shan, H M Liu, W Liu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 28, 2017
[Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results]W W Sui, D H Zou, G An, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 12, 2021
[Analysis of the clinical characteristics and prognosis of 20 patients with multicenter Castleman disease]H S Fan, W W Yan, J Y Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 20, 2022
[Distinguish immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Chinese patients with chronic lymphocytic leukemia]H Li, T Y Wang, Y Yin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 15, 2022
[Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component]Z J Lin, J Zha, S H Yi, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 2, 2016
[Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world]Y L Wan, Y Wang, B C Liu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 22, 2024
[The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia]Y S Huang, W J Xiong, J J Yuan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 7, 2021
[Central nervous system toxicity caused by bortezomib: five case reports and a review of literature]J H Liu, H S Fan, S H Deng, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 26, 2010
Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experienceP Zhang, E-L Jiang, D-L Yang, et al.
Bone Marrow Transplantation|December 20, 2011
An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of ChinaJ Huang, D-H Zou, Z-J Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 25, 2023
[Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma]D D Shan, H M Liu, W Liu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 28, 2017
[Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results]W W Sui, D H Zou, G An, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 12, 2021
[Analysis of the clinical characteristics and prognosis of 20 patients with multicenter Castleman disease]H S Fan, W W Yan, J Y Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 20, 2022
[Distinguish immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Chinese patients with chronic lymphocytic leukemia]H Li, T Y Wang, Y Yin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 15, 2022
[Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component]Z J Lin, J Zha, S H Yi, et al.
Pageof 7